Automated production of a promising radiopharmaceutical (-)-(1-(8-(2-[18F]fluoroethoxy)-3-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)-piperidin-4-yl)(4-fluorophenyl)methanone ([18F]VAT) for the vesicular acetylcholine transporter(VAChT) was achieved using a two-step procedure in a current Good Manufacturing Practices fashion. The production of [18F]VAT was accomplished in approximately 140min, with radiochemical yield of ~15.0% (decay corrected), specific activity>111GBq/μmol, radiochemical purity>99% and mass of VAT ~3.4μg/batch (n>10). The radiopharmaceutical product meets all quality control criteria for human use, and is suitable for clinical PET studies of VAChT.
- Clinical studies
- Positron emission tomography
- Vesicular acetylcholine transporter